Total Debt Summary of FibroGen, Inc.

FibroGen, Inc.'s latest annual total debt in 2023 was 170.45 Million USD , up 89.64% from previous year.
FibroGen, Inc.'s latest quarterly total debt in 2024 Q1 was 168.61 Million USD , down -1.08% from previous quarter.
FibroGen, Inc. reported annual total debt of 89.88 Million USD in 2022, down -9.88% from previous year.
FibroGen, Inc. reported annual total debt of 99.73 Million USD in 2021, up 164.4% from previous year.
FibroGen, Inc. reported quarterly total debt of 168.61 Million USD for 2024 Q1, down -1.08% from previous quarter.
FibroGen, Inc. reported quarterly total debt of 156.23 Million USD for 2023 Q2, up 79.97% from previous quarter.

Annual Total Debt Chart of FibroGen, Inc. (2023 - 2012)

Historical Annual Total Debt of FibroGen, Inc. (2023 - 2012)

Year	Total Debt	Total Debt Growth
2023	170.45 Million USD	89.64%
2022	89.88 Million USD	-9.88%
2021	99.73 Million USD	164.4%
2020	37.72 Million USD	-26.18%
2019	51.1 Million USD	-47.4%
2018	97.15 Million USD	-0.62%
2017	97.76 Million USD	0.42%
2016	97.35 Million USD	0.32%
2015	97.04 Million USD	-0.18%
2014	97.22 Million USD	0.43%
2013	96.8 Million USD	3.84%
2012	93.23 Million USD	0.0%

Year	Total Debt	Total Debt Growth
2024 Q2	163.78 Million USD	-2.87%
2024 Q1	168.61 Million USD	-1.08%
2023 Q2	156.23 Million USD	79.97%
2023 Q4	170.45 Million USD	10.98%
2023 FY	170.45 Million USD	89.64%
2023 Q1	86.81 Million USD	-3.42%
2023 Q3	153.58 Million USD	-1.69%
2022 Q1	96.92 Million USD	-2.82%
2022 FY	89.88 Million USD	-9.88%
2022 Q4	89.88 Million USD	-2.93%
2022 Q3	92.59 Million USD	-1.56%
2022 Q2	94.06 Million USD	-2.95%
2021 Q4	99.73 Million USD	-2.54%
2021 Q2	104.94 Million USD	175.97%
2021 Q3	102.32 Million USD	-2.49%
2021 FY	99.73 Million USD	164.4%
2021 Q1	38.02 Million USD	0.81%
2020 Q4	37.72 Million USD	-10.48%
2020 Q1	47.98 Million USD	-6.11%
2020 Q2	45.37 Million USD	-5.43%
2020 Q3	42.13 Million USD	-7.14%
2020 FY	37.72 Million USD	-26.18%
2019 FY	51.1 Million USD	-47.4%
2019 Q4	51.1 Million USD	-5.55%
2019 Q2	57.19 Million USD	-4.72%
2019 Q1	60.02 Million USD	-38.22%
2019 Q3	54.1 Million USD	-5.4%
2018 Q1	97.62 Million USD	-0.15%
2018 FY	97.15 Million USD	-0.62%
2018 Q4	97.15 Million USD	-0.17%
2018 Q3	97.32 Million USD	-0.15%
2018 Q2	97.47 Million USD	-0.15%
2017 Q1	97.53 Million USD	0.19%
2017 FY	97.76 Million USD	0.42%
2017 Q4	97.76 Million USD	0.4%
2017 Q3	97.37 Million USD	-0.08%
2017 Q2	97.45 Million USD	-0.09%
2016 Q1	97.07 Million USD	0.04%
2016 FY	97.35 Million USD	0.32%
2016 Q4	97.35 Million USD	-0.03%
2016 Q3	97.37 Million USD	-0.02%
2016 Q2	97.39 Million USD	0.33%
2015 Q3	96.99 Million USD	0.06%
2015 Q1	96.87 Million USD	-0.36%
2015 Q2	96.92 Million USD	0.06%
2015 FY	97.04 Million USD	-0.18%
2015 Q4	97.04 Million USD	0.05%
2014 Q4	97.22 Million USD	0.25%
2014 Q3	96.97 Million USD	0.06%
2014 Q2	96.91 Million USD	-15.57%
2014 Q1	114.79 Million USD	18.57%
2014 FY	97.22 Million USD	0.43%
2013 Q4	96.8 Million USD	0.0%
2013 Q1	- USD	0.0%
2013 FY	96.8 Million USD	3.84%
2012 FY	93.23 Million USD	0.0%

Peer Total Debt Comparison of FibroGen, Inc.

Name	Total Debt	Total Debt Difference
Editas Medicine, Inc.	36.53 Million USD	-366.54%
Dynavax Technologies Corporation	256.91 Million USD	33.653%
Supernus Pharmaceuticals, Inc.	41.52 Million USD	-310.468%
Perrigo Company plc	4.07 Billion USD	95.815%
Illumina, Inc.	2.26 Billion USD	92.464%
Thermo Fisher Scientific Inc.	34.91 Billion USD	99.512%
Iovance Biotherapeutics, Inc.	1 Million USD	-16945.5%
Walgreens Boots Alliance, Inc.	9.55 Billion USD	98.216%
IQVIA Holdings Inc.	14.23 Billion USD	98.802%
Heron Therapeutics, Inc.	173.75 Million USD	1.898%
Regeneron Pharmaceuticals, Inc.	2.7 Billion USD	93.694%
Unity Biotechnology, Inc.	26.99 Million USD	-531.549%
Waters Corporation	2.35 Billion USD	92.764%
Biogen Inc.	7.33 Billion USD	97.677%
Sangamo Therapeutics, Inc.	38.1 Million USD	-347.341%
Evolus, Inc.	126.54 Million USD	-34.698%
Adicet Bio, Inc.	17.7 Million USD	-862.859%
Cara Therapeutics, Inc.	43.16 Million USD	-294.873%
bluebird bio, Inc.	330.32 Million USD	48.398%
Esperion Therapeutics, Inc.	540.94 Million USD	68.49%
Agilent Technologies, Inc.	2.73 Billion USD	93.768%
Corbus Pharmaceuticals Holdings, Inc.	20.88 Million USD	-716.19%
Homology Medicines, Inc.	44.05 Million USD	-286.923%
Geron Corporation	85.89 Million USD	-98.437%
Alnylam Pharmaceuticals, Inc.	2.39 Billion USD	92.892%
Amicus Therapeutics, Inc.	445.05 Million USD	61.701%
Myriad Genetics, Inc.	145 Million USD	-17.555%
Viking Therapeutics, Inc.	1.26 Million USD	-13428.175%
Intellia Therapeutics, Inc.	115.34 Million USD	-47.777%
Zoetis Inc.	6.8 Billion USD	97.494%
Abeona Therapeutics Inc.	4.4 Million USD	-3772.217%
Mettler-Toledo International Inc.	2.16 Billion USD	92.137%
BioMarin Pharmaceutical Inc.	1.13 Billion USD	84.967%
Vertex Pharmaceuticals Incorporated	808.4 Million USD	78.915%
Kala Pharmaceuticals, Inc.	36.32 Million USD	-369.276%
Ionis Pharmaceuticals, Inc.	1.45 Billion USD	88.273%
Atara Biotherapeutics, Inc.	57.87 Million USD	-194.538%
Verastem, Inc.	41.55 Million USD	-310.172%
Nektar Therapeutics	230.4 Million USD	26.018%
Axsome Therapeutics, Inc.	186.37 Million USD	8.54%
Aclaris Therapeutics, Inc.	3.07 Million USD	-5445.055%
Sarepta Therapeutics, Inc.	1.39 Billion USD	87.797%
OPKO Health, Inc.	326.56 Million USD	47.803%
Exelixis, Inc.	189.94 Million USD	10.26%
Neurocrine Biosciences, Inc.	428.4 Million USD	60.211%
Corcept Therapeutics Incorporated	151 Thousand USD	-112784.106%
Anavex Life Sciences Corp.	- USD	-Infinity%
uniQure N.V.	138.4 Million USD	-23.153%
Imunon, Inc.	1.13 Million USD	-14861.472%
Blueprint Medicines Corporation	774.12 Million USD	77.981%
Insmed Incorporated	1.2 Billion USD	85.843%
Halozyme Therapeutics, Inc.	1.49 Billion USD	88.631%
Agios Pharmaceuticals, Inc.	56.98 Million USD	-199.107%
TG Therapeutics, Inc.	110.79 Million USD	-53.847%
Incyte Corporation	38.28 Million USD	-345.203%
Emergent BioSolutions Inc.	877.5 Million USD	80.575%

Global Stocks Search

FibroGen, Inc. (0IL8.L)

Total Debt Summary of FibroGen, Inc.

Annual Total Debt Chart of FibroGen, Inc. (2023 - 2012)

Historical Annual Total Debt of FibroGen, Inc. (2023 - 2012)

Peer Total Debt Comparison of FibroGen, Inc.